- Open Access
The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes
© Lasagna-Reeves et al.; licensee BioMed Central Ltd. 2014
- Received: 13 May 2014
- Accepted: 13 May 2014
- Published: 29 May 2014
Pathological aggregation of the microtubule-associated protein tau and subsequent accumulation of neurofibrillary tangles (NFTs) or other tau-containing inclusions are defining histopathological features of many neurodegenerative diseases, which are collectively known as tauopathies. Due to conflicting results regarding a correlation between the presence of NFTs and disease progression, the mechanism linking pathological tau aggregation with cell death is poorly understood. An emerging view is that NFTs are not the toxic entity in tauopathies; rather, tau intermediates between monomers and NFTs are pathogenic. Several proteins associated with neurodegenerative diseases, such as β-amyloid (Aβ) and α-synuclein, have the tendency to form pore-like amyloid structures (annular protofibrils, APFs) that mimic the membrane-disrupting properties of pore-forming protein toxins. The present study examined the similarities of tau APFs with other tau amyloid species and showed for the first time the presence of tau APFs in brain tissue from patients with progressive supranuclear palsy (PSP) and dementia with Lewy bodies (DLB), as well as in the P301L mouse model, which overexpresses mutated tau. Furthermore, we found that APFs are preceded by tau oligomers and do not go on to form NFTs, evading fibrillar fate. Collectively, our results demonstrate that in vivo APF formation depends on mutations in tau, phosphorylation levels, and cell type. These findings establish the pathological significance of tau APFs in vivo and highlight their suitability as therapeutic targets for several neurodegenerative tauopathies.
- Annular protofibrils
The microtubule-associated protein tau plays important cellular roles, including regulating microtubule assembly and stability, axonal transport, and neurite outgrowth. Most of the biological functions of tau are modulated by site-specific phosphorylation. Tau self-assembly, aggregation, and the accumulation of neurofibrillary tangles (NFTs) are hallmarks of Alzheimer’s disease (AD) and other neurodegenerative conditions[3, 4]. Although the importance of tau in AD and other tauopathies is well established[5–7], it is unclear whether NFTs are a primary neurotoxic agent. Most research has focused on NFTs because of the reported correlation between NFT levels in AD brain and disease progression[8–10]; however, recent data suggest that soluble pre-filamentous tau species may be the most toxic and pathologically significant tau aggregates[11, 12]. For instance, cell death and synaptic lesions occur independently of NFT formation in htau mice expressing non-mutant human tau[13, 14]. Furthermore, hippocampal synapse loss and microgliosis precede NFT formation in the P301S transgenic mouse model (P301S Tg), which overexpresses mutated tau. Moreover, in a conditional mouse model (rTg4510) expressing the P301L htau mutant, soluble tau level was found to correlate with neuronal loss and behavioral deficits to a greater degree than NFT level[16, 17].
Soluble oligomers have been implicated as the primary toxic species in many degenerative diseases in which the accumulation of large fibrillar deposits may be inert, protective, or pathological by a different mechanism[18, 19]. However, their structures, interrelationships with other amyloid aggregates, and exact contribution to disease pathogenesis are not entirely clear[20–23]. Amyloid-β (Aβ), α-synuclein, and other amyloidogenic proteins form annular protofibrils (APFs) in vitro; these pore-like structures have been observed in synthetic preparations of both oligomers and fibrils[24, 25]. The formation of pores by Aβ and α-synuclein aggregates are accelerated when the APFs are generated using proteins with mutations associated with familial Alzheimer’s and Parkinson’s diseases, respectively, suggesting that these mutated proteins are more prone to pathogenic activity. More importantly, in addition to the generation of these structures from synthetic peptides, APFs have been isolated from inclusions in the brains of patients with multiple system atrophy (MSA) and AD[28, 29]. Electron microscopy (EM) and atomic force microscopy (AFM) of these structures revealed that they vary in shape and size, lending support to the concept of nonspecific pore formation and membrane leakage. The amyloid pore hypothesis suggests that similar to bacterial pore-forming toxins[31–33], amyloid oligomers/protofibrils induce cell death by disrupting regulated membrane permeability, which disrupts cellular ion and protein homeostasis. Membrane permeabilization is a common pathogenic effect of amyloid oligomers, which are APF precursors. The off pathway conversion of oligomers to APFs, which penetrate the membrane, is an attractive explanation for this toxic effect given the shared assembly state and morphological resemblance between APFs and bacterial pores.
Despite overwhelming evidence supporting amyloid pore formation from biochemical, biophysical, and cell culture experiments, tau pore formation has not been shown in vitro or in vivo. The purpose of the present study was to determine the relationship of tau APFs with other tau amyloid species, such as small oligomers, and to determine if tau APFs are found in human brain samples and the P301L Tg mouse model. Using the well-characterized conformational antibody αAPF, which specifically detects APFs independently of amino acid sequence[28, 29, 31, 35], we found that APFs are preceded by tau oligomers, are on a distinct pathway from NFT formation, and that these pore-like structures are present in human and P301L Tg mouse brain tissue. Furthermore, our results indicate that in vivo APF formation depends on tau phosphorylation, the presence of mutations, and cell type. These findings demonstrate the pathological significance of tau APFs for several neurodegenerative tauopathies and highlight their suitability as therapeutic targets for these diseases.
Preparation of Tau oligomers
Recombinant tau protein (tau-441 [2N4R], MW 45.9 kDa) was expressed and purified as described previously[1, 36]. It was treated with 8 M urea to obtain monomeric tau; then it was dialyzed overnight against 1× PBS buffer (pH 7.4) and adjusted to 1 mg/mL with PBS, and aliquots of tau monomer (in PBS) were stored at -20°C. For oligomer preparation, 300 μL tau stock (1 mg/mL) was added to 700 μL 1× PBS, for a final concentration 0.3 mg/mL. Aβ42 oligomers (7 μL, 0.3 mg/mL) were added to the sample (seeds) and mixed by pipetting for 1 min. The sample was then incubated at room temperature for 1 h on an orbital shaker, and the resulting tau oligomers were used to seed a new batch of tau. This procedure was repeated three times to eliminate the residual Aβ seeds. The preparation and characterization of tau oligomers were performed as described previously[37, 38]. Paired helical filament (PHF) tau fibrils from full-length recombinant tau protein were prepared using heparin according to well-established protocols[1, 36].
Preparation and characterization of Tau APFs
A homogeneous population of pore-like tau APFs was generated by using tau oligomers as the starting material. First, 5% (v/v) hexane was added to a solution of oligomers, and the sample was mixed with a vortex mixer for 1 min every 5 min for a total of 50 min. Then the samples were dialyzed in water, using a molecular mass cut-off membrane of 10 kDa. The morphologies of tau APF preparations were characterized by EM and AFM and purified by size-exclusion chromatography using an LC-6 AD Shimadzu high-performance liquid chromatography (HPLC) system (Shimadzu, Kyoto, Japan) fitted with a Sephacryl S-500 HR (10 × 600 mm) column, (cat number: 17-0613-10; GE Healthcare Life Sciences, Little Chalfont, UK). PBS (pH 7.4) was used as the mobile phase at a 1.5 mL/min flow rate. A gel filtration standard (51–1901; Bio-Rad, Hercules, CA) was used for calibrations.
For each sample, 2 μL was adsorbed onto 200-mesh carbon and Formvar-coated grids, air-dried, and washed for 1 min in distilled water. The samples were negatively stained with 2% uranyl acetate (Ted Pella Inc., Redding, CA) for 2 min and viewed with a Zeiss 10CR microscope (80 kV; Carl Zeiss, Oberkochen, Germany).
The morphologies of synthetic tau APFs and immunoprecipitated structures was assessed by AFM by a non-contact tapping method (ScanAsyst-Air, Bruker, Billerica, MA) using a Multimode 8 AFM machine (Veeco, Plainview, NY).
For liposome preparation, 10 mg phosphatidylcholines (Sigma, St. Louis, MO) was dissolved in 500 μL chloroform (20 mg/mL). The chloroform was evaporated under a stream of nitrogen in the hood, the resulting film was re-hydrated with 500 μL buffer (10 mM HEPES, 100 mM NaCl, pH 7.4), and the solution was intensely vortexed for 3–5 min. Tau oligomers were dissolved to 66 μM in H2O and incubated with liposomes in PBS (1/10 [v/v] liposome/Tau oligomers) for 2 h at room temperature.
Human brain extracts
All postmortem brain tissue used were randomized. Tissue from patients with progressive supranuclear palsy (PSP) and control subjects were provided in frozen blocks by the Brain Resource Center at Johns Hopkins University (Baltimore, MD). Tissue cases were collected with patient consent and handled under protocols approved by the Johns Hopkins Institutional Review Board. PSP samples were examined at the Division of Neuropathology at John Hopkins University. For this study, PSP tissue from the pons was utilized. The dementia with Lewy Bodies (DLB) cases were obtained from the Oregon Brain Bank at Oregon Health and Science University (OHSU, Portland, OR). Tissue use conformed to OHSU Institutional Review Board approved protocols. Neuropathologic assessment conformed to National Institute on Aging-Reagan consensus criteria.
Donor subjects were enrolled and clinically evaluated in studies at the NIH-sponsored Layton Aging and AD Center (ADC) at OHSU. Subjects were participants in brain aging studies at the ADC and received annual neurological and neuropsychological evaluations, with a clinical dementia rating (CDR) assigned by an experienced clinician. Cortex from DLB cases was used in the present study. Each brain tissue sample was homogenized in PBS with a protease inhibitor cocktail (catalog no. 11836145001; Roche Applied Science, Indianapolis, IN), using a dilution of brain: PBS of 1:3 (w/v). Samples were then centrifuged at 10,000 rpm for 10 min at 4°C. The supernatants were portioned into aliquots, snap-frozen, and stored at -80°C until use.
Transgenic mouse model
P301L (JNPL3) mice (Taconic Farms) were used for our experiments, including biochemical and immunohistochemistry (IHC) analyses. The JNPL3 mouse model expresses a frontotemporal lobar degeneration-associated human mutant tau transgene (P301L). Mice were housed at the University of Texas Medical Branch (UTMB) animal care facility and were maintained according to USDA standards (12-h light/dark cycle, food and water ad libitum), in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD). Animals were anesthetized according to UTMB Institutional Animal Care and Use Committee-approved procedures. Tissue was collected from 2-, 4-, 7-, 10-, and 12-month-old animals. Prior to euthanasia, mice were deeply anesthetized and perfused transcardially with 1× PBS prior to decapitation. Animals were anesthetized according to IACUC-approved procedures for animal sacrifice. After sacrifice, brains and spinal cords were dissected and stored at -80°C. Mouse tissue was homogenized as previously described for human samples.
Immunoprecipitation of APFs from human brain tissue
The characterization and specificity of the αAPF conformation-specific antibody was published previously. For immunoprecipitation experiments, tosyl-activated magnetic Dynabeads (Dynal Biotech, Lafayette Hill, PA) were coated with 11.25 μg αAPF antibody (2.6 mg/mL) and diluted in 0.1 M borate (pH 9.5) overnight at 37°C. Beads were washed (0.2 M Tris, 0.1% bovine serum albumin [BSA], pH 8.5) and then incubated with either DLB or control patient brain homogenate with rotation at RT for 1 h. Beads were then washed three times with PBS and eluted using 0.1 M glycine (pH 2.8). The pH of each eluted fraction was adjusted using to pH 8.0 with 1 M Tris. Finally, some fractions were applied to a nitrocellulose membrane for dot blotting with the Tau-5 antibody (Covance, Princeton, NJ). Other fractions were again co-immunoprecipitated using spin columns (Cat# 26149, Thermo Scientific, Waltham, MA) coated with Tau-5 antibody to ensure the presence of tau APFs for subsequent AFM imaging.
Each sample (2 μl) was applied to a nitrocellulose membrane, blocked with 10% nonfat milk in Tris-buffered saline with Tween (TBS-T) overnight at 4°C, washed three times for 5 min each with TBS-T, and incubated for 1 h at RT with the anti-APF antibody αAPF (1:1000) for the synthetic samples and the anti-tau antibody Tau-5 (1:5000) for the immunoprecipitated samples. The membranes were washed three times for 5 min each with TBS-T, incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Promega, Madison, WI) diluted 1:10000 in 3% BSA/TBS-T, and incubated for 1 h at room temperature. The blots were washed 3 times with TBS-T and developed with an enhanced chemiluminescence kit from (RPN2132; Amersham-Pharmacia/GE Healthcare Life Sciences, Little Chalfont, UK).
Paraffin-embedded brain sections from DLB, PSP, and control subjects and JNPL3 mice were hydrated using xylene, 100% ethanol, 95% ethanol, 80% ethanol, and distilled water. Then, the sections were heated by microwave (750 watts) in target solution (Dako, Glostrup, Denmark) twice for 4 min each. The tissues were washed in 1× PBS, three times for 5 min each, and blocked for 45 min with 5% horse serum in PBS. The tissues were incubated with rabbit anti-APF antibody αAPF antibody (1:350) overnight. Then the sections were washed three times with 1× PBS for 10 min each. The sections were incubated with the secondary antibody anti-rabbit Alexa Fluor 568 (1:700; Invitrogen, Carlsbad, CA) for 60 min. Then, the sections were washed three times with 1× PBS for 5 min each and blocked again with 5% horse serum in PBS for 30 min. The sections were then washed three times for 10 min each time in PBS before incubation overnight with the following antibodies: mouse anti-tau Tau-5 (1:1000), anti-phospho tau (Ser202/Thr205) AT8 (1:1000, Thermo Fisher), glial fibrillary acid protein (GFAP) (1:5000, Covance), NeuN (1:3000, Chemicon International Inc., Temecula, CA), myelin oligodendrocyte glycoprotein (MOG) (1:800; LifeSpan Biosciences, Seattle, WA) anti-Aβ 4G8 (1:800, Covance), and anti-α-synuclein 4D6 (1:700, Covance). The next day, the sections were washed three times in PBS for 10 min each before incubation with goat anti-mouse IgG Alexa Fluor 488 (1:700, Invitrogen) for 1 h. Sections were washed and mounted in Vectashield mounting medium with 4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA). The sections were examined using a Bio-Rad Radiance 2100 confocal system (Bio-Rad, Hercules, CA) mounted on a Nikon Eclipse E800 microscope (Nikon, Tokyo, Japan) equipped with a CoolSnap-FX monochrome CCD camera (Photometrics, Tucson, AZ) using a standard Nikon FITC, TX Red, and DAPI filter set for Alexa Fluor 488 and 568 and DAPI, respectively.
Paraffin-embedded brain tissue sections from DLB, PSP, and control subjects and JNPL3 mice were hydrated using xylene, 100% ethanol, 95% ethanol, 80% ethanol, and distilled water. The hydrated sections were heated twice for 4 min each in target solution (Dako) using a microwave oven (750 watts). Tissues were then washed in 1× PBS three times for 5 min each and blocked for 10 min with 3% H2O2 in PBS. Tissues were then washed in 1× PBS three times for 5 min each and blocked for 60 min with 5% horse serum in PBS. The tissues were incubated with αAPF antibody (1:350) overnight. The sections were then washed three times with 1× PBS for 10 min each, followed by a 60-min incubation with the secondary biotinylated anti-rabbit antibody (Pierce Biotechnology, Rockford, IL). The sections were washed three times with 1× PBS for 5 min each. The sections were then incubated for 30 min using an ABC kit and washed with 1× PBS three times for 5 min each. Finally, the sections were incubated with 3,3′-diaminobenzidine (DAB) for 5 min.
Tau APF formation induced by myelin basic protein (MBP)
Purified human MBP (Chemicon International, Temecula, CA) was resuspended in 20 mM sodium acetate and 100 mM sodium chloride (pH 4.0), dialyzed into PBS, and stored at -80°C at 1 mg/mL. Tau oligomers (0.3 mg/mL) were incubated at 37°C with rocking, either alone or with 1.56 μM MBP or 1.56 μM bovine lactalbumin. Control samples containing Aβ oligomers and 1.56 μM MBP or 1.56 μM MBP in PBS were also included. At each time point, 100 μL samples of each reaction were placed in a 96-well microplate in triplicate, and the amount of APF formation was determined by enzyme-linked immunosorbent assay (ELISA) using the αAPF antibody.
For ELISA, plates were coated with 100 μL sample using 0.1 M sodium bicarbonate (pH 9.6) as coating buffer, followed by overnight incubation at 4°C and three washes with TBS-T (0.01% Tween). Then, plates were blocked for 1 h at RT with 10% BSA (IgG-free TBS-T). The plates were then washed three times with TBS-T before the primary antibody (αAPF, 1:500; T22, 1:1000; Tau5 1:1000) was added and allowed to react for 1 h at RT. The plates were then washed three times with TBS-T, and 100 μL HRP-conjugated anti-rabbit IgG or anti-mouse IgG (diluted 1:10,000 in 5% nonfat milk in TBS-T; Promega) was added, followed by incubation for 1 h at RT. Finally, plates were washed three times with TBS-T and developed with 3,3,5,5-tetramethylbenzidine (TMB-1 component substrate) from KPL (Gaithersburg, MD). The reaction was stopped with 100 μL 1 M HCl, and samples were read at 450 nm. Statistical analyses were based on a two-way analyses of variance (ANOVAs), performed using Origin-8 software (Origin Lab, Northampton, MA).
For competitive ELISA, plates were coated with 100 ng tau oligomer (for T22) or APF (for αAPF) using 0.1 M sodium bicarbonate (pH 9.6) as the coating buffer, followed by overnight incubation at 4°C. This protocol follows the same directions indicated for the direct ELISA with the exception that αAPF and T22 were pre-incubated with tau monomers, oligomers, APFs, or fibrils for 45 min. During the incubation, the amount of antibody was four times greater than that of each tau species. Six samples were run for each condition. For statistical analysis, two-way ANOVA was performed using Origin-8 software.
Cell toxicity assay
Neuron viability was assessed using the MTT colorimetric assay (Invitrogen) as previously described. Briefly, SH-SY5Y human neuroblastoma cells were treated with 2 μM tau oligomers, monomers, or APFs. After incubation for 6 h at 37°C, the cells were assayed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) toxicity assay kit (Tox-1) (Sigma) according to the manufacturer’s directions. All measurements were made in triplicate. Statistical analyses were based on a two-way ANOVAs, which were performed using Origin-8 software.
SH-SY5Y cells were treated with 2 μM tau oligomers or monomers for 6 h. Then, the cells on the coverslip were fixed and permeabilized. The samples were blocked for 1 h in 5% goat serum and incubated overnight at 4°C with Tau-5 (1:1000). Sections were then washed and incubated with an Alexa 488-conjugated goat anti-mouse antibody (1:700, Invitrogen) for 1 h at RT. Sections were then incubated overnight at 4°C with αAPF (1:350), then washed and incubated with an Alexa 568-conjugated goat anti-mouse antibody (1:700). DAPI was used to stain the nuclei (1:4000, Invitrogen). Sections were then washed for 30 min and coverslipped.
Tau oligomers form APFs in vitro
Tau APFs are present in DLB and PSP brain tissue and are on a distinct pathway from hyperphosphorylated NFT formation
Because tau APFs are best prepared from tau oligomers in vitro, DLB brain sections were also analyzed for the presence of tau oligomers colocalized with APFs by immunofluorescent double labeling with αAPF and T22, a polyclonal conformation-specific antibody against tau oligomers. Partial colocalization between tau oligomers and APFs was seen (Additional file3: Figure S3), which is in agreement with the model suggesting that oligomers form initially and proceed on a separate APF formation pathway.
Tau APFs are present in the JNPL3 mouse model
We next investigated whether APFs are present in the JNPL3 mouse model of tauopathy, which expresses the frontotemporal lobar degeneration-associated human mutant tau transgene P301L under the prion promoter. Mouse brain tissues were collected at different ages (2, 4, 7, 10, and 12 months) and biochemically analyzed for the presence of tau APFs, which were found to increase in an age-dependent fashion and peak at 10 months (Figure 5a). This finding is in accordance with a publication that reported that nearly 90% of JNPL3 mice develop motor and behavioral disturbances at 10 months old. The decrease in tau APF levels in older mice (12 months) could be explained by the cellular loss that occurs in the model at that age. JNPL3 brain sections were then used in αAPF IHC experiments, which revealed APFs in the brainstem (Figure 5b). To verify that APF were comprised of tau protein, JNPL3 brain sections were double labeled with Tau-5 and αAPF. The results revealed that APFs colocalized with Tau-5 (Figure 5c). Conversely, no colocalization was observed following double labeling with AT8 and αAPF, demonstrating that tau APFs are not phosphorylated at epitopes Ser202/Thr205 (Figure 5c), similarly to human brain sections from patients with DLB. Next, cell specificity was examined by immunofluorescently labeling mouse brain sections. Tau APFs were detected in oligodendrocytes and neurons but not astrocytes (Figure 5d).
Because tau APFs were mainly detected in oligodendrocytes in DLB and PSP patient brains and JNPL3 mouse brain and spinal cord, we studied the ability of MBP to induce the formation of APFs from tau oligomers. We incubated tau oligomers with MBP and performed kinetic analyses of APF formation with ELISAs using the αAPF antibody (Additional file6: Figure S6a). The results show that mixing MBP with tau oligomers induces tau APF formation as early as 30 min after starting the incubation. Samples were also analyzed by AFM, which detected APFs after 3 h of incubation (Additional file6: Figure S6b). No APFs were detected when Aβ oligomers were mixed with MBP or tau was mixed with lactalbumin, suggesting that this MBP-triggered process is specific for tau.
To our knowledge, this is the first study to describe the formation of tau APFs both in vitro and in vivo. However, the association of tau with the plasma membrane has been extensively described[52–54]. The authors of one study demonstrated a phosphorylation-dependent dynamic association between tau and the neuronal membrane. Specifically, they showed that that dephosphorylation of tau at epitopes (including Ser202/Thr205) results in its translocation from the cytosol to the membrane, and this process is dependent on a direct interaction between Fyn and tau via the fyn-SH3 domain. The function of plasma membrane-associated tau remains unclear; nevertheless, accumulating evidence suggests that the interaction between tau and Fyn might be crucial for the tau-mediated regulation of intracellular signaling. Bhaskar and colleagues demonstrated that the affinity between Fyn and tau was increased 25–45 fold by the tau P301L mutation, which is the same mutation in the JNPL3 mouse model used in our study. This could explain the high amount of tau APFs detected in the JNPL3 model. Moreover, a recent study by Flach et al. revealed that tau oligomers impair artificial membrane integrity and cellular viability. The authors showed that tau oligomers produce a deleterious effect on membrane permeabilization in SH-SY5Y cells. Furthermore, they corroborated these observations with a vesicle permeabilization assay, where they measured leakage of the fluorescent dye ANTS out of phospholipid vesicles. The authors observed a more pronounced effect in vesicles treated with tau oligomers rather than monomers or fibrils, suggesting that the cellular membrane might be a primary target of tau oligomers. Collectively, the existing evidence suggests that tau oligomers that are not phosphorylated at Ser202/Thr204 could interact with Fyn and be taken into the plasma membrane given a suitable environment for tau APF formation. On the other hand, if tau oligomers continue their aggregation process and become phosphorylated at Ser202/Thr205, no interaction with Fyn will occur, leading to NFT formation. Further studies are necessary to establish the direct relationship between Fyn and tau APF formation.
EM analysis of pores isolated from human brains with AD and MSA inclusions revealed that they are indeed composed of individual spherical oligomers that vary in shape and size, lending support to the notion of nonspecific pore formation and membrane leakage[28, 58]. Nevertheless, other laboratories reported the ability of oligomers to form calcium channels in lipid bilayers and neuronal cells[59–61]. A study from Jang et al. reported the ability of Aβ oligomers to assemble into pores with single-channel conductance that allow calcium uptake. Our results do not rule out the possibility of channel activity by tau pores. Either through the formation of channels or through nonspecific ion leakage, tau oligomers and APFs may lead to an influx of calcium and its subsequent dysregulation. NMDA receptor antagonists, such as memantine, block extrasynaptic calcium release and have been shown to be neuroprotective. Recently, Kokubo et al. reported that APFs were found not only on plasma membranes but also on vesicles inside of cell processes by immuno-EM using an αAPF antibody in transgenic mice expressing a mutant form of amyloid precursor protein. This evidence suggests that several cellular environments can promote the formation of these annular structures. This last point was confirmed by our results showing tau APFs in different subcellular localizations, indicating that tau APFs are formed in both plasma and organelle membranes (Figure 6b). The present study also demonstrated that tau APFs are located in different cell types in DLB and PSP brains and JPNL3 brain sections and spinal cord. It is possible that the cell type in which tau APFs are formed will condition the clinical symptoms in different tauopathies or behavioral impairments in tau transgenic mouse models. Nevertheless, it is important to consider that P301L tau in the JNPL3 mouse model is expressed under the prion promoter, which is mainly expressed in neurons but also in oligodendrocytes and astrocytes. This is extremely important considering that it is well-known that tau is not expressed in astrocytes, suggesting different sources of tau in the formation of APFs in human tauopathies and the JNPL3 mouse model. While the presence of tau APFs in JPNL3 astrocytes could merely be due to the expression of tau in these cells, in the case of human tauopathies, the presence of these tau structures would be better explained by the internalization of exogenous tau into the astrocytes, which was previously suggested for Aβ and α-synuclein[29, 65].
We observed tau pores in oligodendrocytes in all of the studied samples. Several publications have demonstrated the relevance of tau aggregation in oligodendrocytes in different tauopathies and many mouse models[39, 42, 66–68]. Furthermore, a study by Klein et al. showed that Fyn interacts with tau in oligodendrocytes to promote myelination. Specifically, the authors demonstrated that Fyn activation in lipid raft microdomains leads to an increased binding to tau and its recruitment to the area of contact with the neuronal axon. This concept is also supported by our in vitro data showing that MBP induces the formation of tau APFs, suggesting that areas rich in MBP are more prone to induce tau APF formation. The ability of MBP to induce the formation of annular structures from amyloid oligomers appears to be sequence-specific and is not a general mechanism for all amyloidogenic proteins (e.g., Aβ), which fails to form APFs in the presence of MBP. Nevertheless, previous studies have demonstrated that MBP binds to Aβ and inhibits amyloid fibril formation[70–72], suggesting that MBP does have some influence on the aggregation process of other amyloidogenic proteins.
Our novel findings linking tau oligomers with tau APFs enhance the understanding of amyloid oligomer-mediated neurodegeneration in vivo and underscore the complexity of tau structures in several tauopathies. Understanding the fundamentals of in vivo tau pore formation and properties is critical for establishing potential links between tau aggregation and the mechanisms of cellular toxicity that occur during neurodegenerative disease progression. Still, additional research should examine the nature of these tau pores and determine whether they represent single channels or nonspecific pores and clarify their relationship with Fyn.
This work was supported by the Cullen Trust, the Alzheimer’s Drug Discovery Foundation (ADDF), and the Mitchell Center for Neurodegenerative Diseases. We thank Dr. Maxime Rousseaux for his suggestions and critical reading of the manuscript and Dr. Lindsay Reese of SciReviser for editing the manuscript. PSP tissues for this research were provided by the Johns Hopkins University Morris Udall Parkinson’s Disease Center of Excellence (NINDS P50 NS38377) and Alzheimer’s Disease Research Center (NIA P50 AG05146).
- Binder LI, Frankfurter A, Rebhun LI: The distribution of tau in the mammalian central nervous system. J Cell Biol 1985, 101(4):1371–1378. 10.1083/jcb.101.4.1371View ArticlePubMedGoogle Scholar
- Drechsel DN, Hyman AA, Cobb MH, Kirschner MW: Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 1992, 3(10):1141–1154. 10.1091/mbc.3.10.1141View ArticlePubMedPubMed CentralGoogle Scholar
- Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24: 1121–1159. doi:10.1146/annurev.neuro.24.1.1121 10.1146/annurev.neuro.24.1.1121View ArticlePubMedGoogle Scholar
- Alonso AC, Li B, Grundke-Iqbal I, Iqbal K: Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2008, 5(4):375–384. 10.2174/156720508785132307View ArticlePubMedGoogle Scholar
- Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I: Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009, 118(1):53–69. doi:10.1007/s00401–009–0486–3 10.1007/s00401-009-0486-3View ArticlePubMedPubMed CentralGoogle Scholar
- Ballatore C, Lee VM, Trojanowski JQ: Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 2007, 8(9):663–672. doi:10.1038/nrn2194View ArticlePubMedGoogle Scholar
- Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP: Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol Aging 2007, 28(1):1–7. doi:10.1016/j.neurobiolaging.2005.11.001 10.1016/j.neurobiolaging.2005.11.001View ArticlePubMedGoogle Scholar
- Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82(4):239–259. 10.1007/BF00308809View ArticlePubMedGoogle Scholar
- Delacourte A, Buee L: Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurol 2000, 13(4):371–376. 10.1097/00019052-200008000-00002View ArticlePubMedGoogle Scholar
- Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112(4):389–404. doi:10.1007/s00401–006–0127-z 10.1007/s00401-006-0127-zView ArticlePubMedPubMed CentralGoogle Scholar
- Brunden KR, Trojanowski JQ, Lee VM: Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis 2008, 14(4):393–399.PubMedPubMed CentralGoogle Scholar
- Marx J: Alzheimer’s disease. A new take on tau. Science 2007, 316(5830):1416–1417. doi:10.1126/science.316.5830.1416 10.1126/science.316.5830.1416View ArticlePubMedGoogle Scholar
- Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P: Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005, 25(22):5446–5454. doi:10.1523/JNEUROSCI.4637–04.2005 10.1523/JNEUROSCI.4637-04.2005View ArticlePubMedGoogle Scholar
- Polydoro M, Acker CM, Duff K, Castillo PE, Davies P: Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009, 29(34):10741–10749. doi:10.1523/JNEUROSCI.1065–09.2009 10.1523/JNEUROSCI.1065-09.2009View ArticlePubMedPubMed CentralGoogle Scholar
- Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53(3):337–351. doi:10.1016/j.neuron.2007.01.010 10.1016/j.neuron.2007.01.010View ArticlePubMedGoogle Scholar
- Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C: Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007, 27(14):3650–3662. doi:10.1523/JNEUROSCI.0587–07.2007 10.1523/JNEUROSCI.0587-07.2007View ArticlePubMedGoogle Scholar
- Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT: Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006, 168(5):1598–1607. doi:10.2353/ajpath.2006.050840 10.2353/ajpath.2006.050840View ArticlePubMedPubMed CentralGoogle Scholar
- Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8(2):101–112. doi:10.1038/nrm2101 10.1038/nrm2101View ArticlePubMedGoogle Scholar
- Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, Chiti F, Dobson CM, Stefani M: Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci 2006, 26(31):8160–8167. doi:10.1523/JNEUROSCI.4809–05.2006 10.1523/JNEUROSCI.4809-05.2006View ArticlePubMedGoogle Scholar
- Ross CA, Poirier MA: Opinion: what is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 2005, 6(11):891–898. doi:10.1038/nrm1742 10.1038/nrm1742View ArticlePubMedGoogle Scholar
- Caughey B, Lansbury PT: Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003, 26: 267–298. doi:10.1146/annurev.neuro.26.010302.081142 010302.081142 10.1146/annurev.neuro.26.010302.081142View ArticlePubMedGoogle Scholar
- Glabe CG: Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006, 27(4):570–575. doi:10.1016/j.neurobiolaging.2005.04.017 10.1016/j.neurobiolaging.2005.04.017View ArticlePubMedGoogle Scholar
- Miller Y, Ma B, Nussinov R: Synergistic interactions between repeats in tau protein and Abeta amyloids may be responsible for accelerated aggregation via polymorphic states. Biochemistry 2011, 50(23):5172–5181. doi:10.1021/bi200400u 10.1021/bi200400uView ArticlePubMedPubMed CentralGoogle Scholar
- Hafner JH, Cheung CL, Woolley AT, Lieber CM: Structural and functional imaging with carbon nanotube AFM probes. Prog Biophys Mol Biol 2001, 77(1):73–110. 10.1016/S0079-6107(01)00011-6View ArticlePubMedGoogle Scholar
- Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr: Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002, 41(32):10209–10217. 10.1021/bi020139hView ArticlePubMedGoogle Scholar
- Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr: Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418(6895):291.View ArticlePubMedGoogle Scholar
- Pountney DL, Lowe R, Quilty M, Vickers JC, Voelcker NH, Gai WP: Annular alpha-synuclein species from purified multiple system atrophy inclusions. J Neurochem 2004, 90(2):502–512. 10.1111/j.1471-4159.2004.02533.xView ArticlePubMedGoogle Scholar
- Lasagna-Reeves CA, Glabe CG, Kayed R: Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem 2011, 286(25):22122–22130. doi:10.1074/jbc.M111.236257 10.1074/jbc.M111.236257View ArticlePubMedPubMed CentralGoogle Scholar
- Lasagna-Reeves CA, Kayed R: Astrocytes contain amyloid-beta annular protofibrils in Alzheimer’s disease brains. FEBS Lett 2011, 585(19):3052–3057. doi:10.1016/j.febslet.2011.08.027 10.1016/j.febslet.2011.08.027View ArticlePubMedGoogle Scholar
- Lashuel HA, Lansbury PT Jr: Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 2006, 39(2):167–201. doi:10.1017/S0033583506004422 10.1017/S0033583506004422View ArticlePubMedGoogle Scholar
- Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C: Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 2009, 284(7):4230–4237. doi:10.1074/jbc.M808591200 10.1074/jbc.M808591200View ArticlePubMedPubMed CentralGoogle Scholar
- Montoya M, Gouaux E: Beta-barrel membrane protein folding and structure viewed through the lens of alpha-hemolysin. Biochim Biophys Acta 2003, 1609(1):19–27. 10.1016/S0005-2736(02)00663-6View ArticlePubMedGoogle Scholar
- Parker MW, Feil SC: Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol 2005, 88(1):91–142. 10.1016/j.pbiomolbio.2004.01.009View ArticlePubMedGoogle Scholar
- Glabe CG, Kayed R: Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 2006, 66(2 Suppl 1):S74-S78. doi:10.1212/01.wnl.0000192103.24796.42View ArticlePubMedGoogle Scholar
- Kokubo H, Kayed R, Glabe CG, Staufenbiel M, Saido TC, Iwata N, Yamaguchi H: Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. Int J Alzheimers Dis 2009., 2009: doi:10.4061/2009/689285Google Scholar
- Margittai M, Langen R: Template-assisted filament growth by parallel stacking of tau. Proc Natl Acad Sci USA 2004, 101(28):10278–10283. doi:10.1073/pnas.0401911101 0401911101 10.1073/pnas.0401911101View ArticlePubMedPubMed CentralGoogle Scholar
- Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R: Preparation and characterization of neurotoxic tau oligomers. Biochemistry 2010, 49(47):10039–10041. doi:10.1021/bi1016233 10.1021/bi1016233View ArticlePubMedGoogle Scholar
- Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R: Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 2011, 6: 39. doi:10.1186/1750–1326–6-39 10.1186/1750-1326-6-39View ArticlePubMedPubMed CentralGoogle Scholar
- Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000, 25(4):402–405. doi:10.1038/78078 10.1038/78078View ArticlePubMedGoogle Scholar
- Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R: Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J 2012, 26(5):1946–1959. doi:10.1096/fj.11–199851 10.1096/fj.11-199851View ArticlePubMedPubMed CentralGoogle Scholar
- Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, Lees A, Yamamoto T, Kosaka K: Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol 2003, 105(3):265–270. doi:10.1007/s00401–002–0644–3PubMedGoogle Scholar
- Yoshida M: Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 2006, 26(5):457–470. 10.1111/j.1440-1789.2006.00743.xView ArticlePubMedGoogle Scholar
- Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 2002, 103(1):26–35. 10.1007/s004010100423View ArticlePubMedGoogle Scholar
- Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C, Hall JE: Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 2006, 128(6):637–647. doi:10.1085/jgp.200609533 10.1085/jgp.200609533View ArticlePubMedPubMed CentralGoogle Scholar
- Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R: Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 2005, 102(30):10427–10432. doi:10.1073/pnas.0502066102 10.1073/pnas.0502066102View ArticlePubMedPubMed CentralGoogle Scholar
- Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG: Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004, 279(45):46363–46366. doi:10.1074/jbc.C400260200 C400260200 10.1074/jbc.C400260200View ArticlePubMedGoogle Scholar
- Engel MF, Khemtemourian L, Kleijer CC, Meeldijk HJ, Jacobs J, Verkleij AJ, de Kruijff B, Killian JA, Hoppener JW: Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc Natl Acad Sci USA 2008, 105(16):6033–6038. doi:10.1073/pnas.0708354105 10.1073/pnas.0708354105View ArticlePubMedPubMed CentralGoogle Scholar
- Zhu M, Li J, Fink AL: The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem 2003, 278(41):40186–40197. 10.1074/jbc.M305326200View ArticlePubMedGoogle Scholar
- Chen F-Y, Lee M-T, Huang HW: Evidence for membrane thinning effect as the mechanism for peptide-induced pore formation. Biophys J 2003, 84(6):3751–3758. 10.1016/S0006-3495(03)75103-0View ArticlePubMedPubMed CentralGoogle Scholar
- Modler AJ, Gast K, Lutsch G, Damaschun G: Assembly of amyloid protofibrils via critical oligomers–a novel pathway of amyloid formation. J Mol Biol 2003, 325(1):135–148. 10.1016/S0022-2836(02)01175-0View ArticlePubMedGoogle Scholar
- Porat Y, Kolusheva S, Jelinek R, Gazit E: The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 2003, 42(37):10971–10977. 10.1021/bi034889iView ArticlePubMedGoogle Scholar
- Pooler AM, Hanger DP: Functional implications of the association of tau with the plasma membrane. Biochem Soc Trans 2010, 38(4):1012–1015. doi:10.1042/BST0381012 10.1042/BST0381012View ArticlePubMedGoogle Scholar
- Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP: Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 2012, 33(2):431. e427–438. doi:10.1016/j.neurobiolaging.2011.01.005View ArticlePubMedGoogle Scholar
- Maas T, Eidenmuller J, Brandt R: Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 2000, 275(21):15733–15740. doi:10.1074/jbc.M000389200 10.1074/jbc.M000389200View ArticlePubMedGoogle Scholar
- Bhaskar K, Yen SH, Lee G: Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem 2005, 280(42):35119–35125. doi:10.1074/jbc.M505895200 10.1074/jbc.M505895200View ArticlePubMedGoogle Scholar
- Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 2010, 142(3):387–397. doi:10.1016/j.cell.2010.06.036 10.1016/j.cell.2010.06.036View ArticlePubMedGoogle Scholar
- Flach K, Hilbrich I, Schiffmann A, Gartner U, Kruger M, Leonhardt M, Waschipky H, Wick L, Arendt T, Holzer M: Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem 2012, 287(52):43223–43233. doi:10.1074/jbc.M112.396176 10.1074/jbc.M112.396176View ArticlePubMedPubMed CentralGoogle Scholar
- Pountney DL, Lowe R, Quilty M, Vickers JC, Voelcker NH, Gai WP: Annular alpha-synuclein species from purified multiple system atrophy inclusions. J Neurochem 2004, 90(2):502–512. doi:10.1111/j.1471–4159.2004.02533.x 10.1111/j.1471-4159.2004.02533.xView ArticlePubMedGoogle Scholar
- Arispe N, Pollard HB, Rojas E: Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1–40)] in bilayer membranes. Proc Natl Acad Sci USA 1993, 90(22):10573–10577. 10.1073/pnas.90.22.10573View ArticlePubMedPubMed CentralGoogle Scholar
- Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC: The channel hypothesis of Alzheimer’s disease: current status. Peptides 2002, 23(7):1311–1315. 10.1016/S0196-9781(02)00067-0View ArticlePubMedGoogle Scholar
- Di Scala C, Troadec J-D, Lelièvre C, Garmy N, Fantini J, Chahinian H: Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β-amyloid peptide. J Neurochem 2013. n/a-n/a. doi:10.1111/jnc.12390Google Scholar
- Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, Nussinov R, Lal R: Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer’s disease and down syndrome. Proc Natl Acad Sci USA 2010, 107(14):6538–6543. doi:10.1073/pnas.0914251107 10.1073/pnas.0914251107View ArticlePubMedPubMed CentralGoogle Scholar
- Bordji K, Becerril-Ortega J, Buisson A: Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer’s disease. Rev Neurosci 2011., 22: doi:10.1515/rns.2011.029Google Scholar
- Yamaguchi H, Maat-Schieman ML, van Duinen SG, Prins FA, Neeskens P, Natte R, Roos RA: Amyloid beta protein (Abeta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects. J Neuropathol Exp Neurol 2000, 59(8):723–732.View ArticlePubMedGoogle Scholar
- Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ: Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010, 285(12):9262–9272. doi:10.1074/jbc.M109.081125 10.1074/jbc.M109.081125View ArticlePubMedPubMed CentralGoogle Scholar
- Nishimura M, Tomimoto H, Suenaga T, Namba Y, Ikeda K, Akiguchi I, Kimura J: Immunocytochemical characterization of glial fibrillary tangles in Alzheimer’s disease brain. Am J Pathol 1995, 146(5):1052–1058.PubMedPubMed CentralGoogle Scholar
- Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M: Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002, 22(21):9340–9351.PubMedGoogle Scholar
- Ren Y, Lin WL, Sanchez L, Ceballos C, Polydoro M, Spires-Jones TL, Hyman BT, Dickson DW, Sahara N: Endogenous Tau Aggregates in Oligodendrocytes of rTg4510 Mice Induced by Human P301L Tau. J Alzheimers Dis 2013. doi:10.3233/JAD-130986Google Scholar
- Klein C, Kramer EM, Cardine AM, Schraven B, Brandt R, Trotter J: Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau. J Neurosci 2002, 22(3):698–707.PubMedGoogle Scholar
- Hoos MD, Ahmed M, Smith SO, Van Nostrand WE: Myelin basic protein binds to and inhibits the fibrillar assembly of Abeta42 in vitro. Biochemistry 2009, 48(22):4720–4727. doi:10.1021/bi900037s 10.1021/bi900037sView ArticlePubMedPubMed CentralGoogle Scholar
- Liao MC, Hoos MD, Aucoin D, Ahmed M, Davis J, Smith SO, Van Nostrand WE: N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly. J Biol Chem 2010, 285(46):35590–35598. doi:10.1074/jbc.M110.169599 10.1074/jbc.M110.169599View ArticlePubMedPubMed CentralGoogle Scholar
- Liao MC, Ahmed M, Smith SO, Van Nostrand WE: Degradation of amyloid beta protein by purified myelin basic protein. J Biol Chem 2009, 284(42):28917–28925. doi:10.1074/jbc.M109.050856 10.1074/jbc.M109.050856View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.